Mediar Therapeutics
MA - BostonBiotechnology
Focus: Mediar Therapeutics is a Boston-based antibody therapy company focused on respiratory diseases, currently in early-stage clinical development. The company operates as a clinical-stage biotech with a pipeline spanning Phase 1 and Phase 2 programs.
Profile data last refreshed 3h ago · AI intelligence enriched 1mo ago
Open Jobs
1
Should You Work at Mediar Therapeutics?
AI assessmentBest suited for early-career scientists and clinical developers comfortable with clinical-stage risk and willing to build core competencies; not ideal for those seeking stability or near-term commercial upside.
Why Work Here
- Ground-floor opportunity at an antibody-focused biotech with respiratory disease focus, still early enough to shape company culture and scientific direction
Data completeness
2/9 — Limited
Company HealthSolid
Pipeline
Early-stage
6 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
MTX-463
HealthyClinical Trials (1)
NCT06401213A First-in-Human Safety Trial of MTX-463
Phase 1Help build intelligence for Mediar Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.